Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249634 · ClinicalTrials.gov registry record · Phase 2
Testosterone Treatment in Men with Chronic Kidney Disease
A Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic, sponsored by St. Louis University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05249634 is a Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic that is actively recruiting participants, run by St. Louis University. The registered enrollment target is 20 participants, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05249634, a Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic, is actively recruiting participants, sponsored by St. Louis University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
Conditions Studied
Interventions
- DRUG Jatenzo Pill
Study Locations (1)
Missouri
- Saint Louis Univeristy - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05249634
The ClinicalTrials.gov registry entry for NCT05249634 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (82% lower). The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Jatenzo Pill is the first listed.
NCT05249634 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05249634 about?
NCT05249634 is a clinical study titled "Testosterone Treatment in Men with Chronic Kidney Disease". This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
What is the current status of trial NCT05249634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-03-15. Estimated completion is 2028-12.
What conditions does trial NCT05249634 study?
This clinical trial studies the following conditions: Hypogonadism, Male, Kidney Disease, Chronic.
What interventions are being tested in trial NCT05249634?
The interventions under investigation include: Jatenzo Pill (DRUG).
Who is sponsoring clinical trial NCT05249634?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05249634 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
Clomid in Men With Low Testosterone With and Without Prior Treatment
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.